【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2012 8
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2012 8
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2012 10
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2012 11
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2012 12
2.4.1 Abbott Completes Private Placement of Notes for $14.7 Billion 12
2.4.2 Roche Revises Offer Price to Acquire Illumina for Up to $8.2 Billion 12
2.4.3 UnitedHealth Group to Acquire 90% Stake in Amil Participacoes for $4.9 Billion 12
2.4.4 HCA Completes Public Offering of Notes for $3.5 Billion 13
2.4.5 HCP Completes Acquisition of Senior Housing Portfolio of Emeritus and Blackstone for $1.7 Billion 13
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 14
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2012 14
3.1.1 Top M&A Deals in Q4 2012 15
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2011 – Q4 2012 16
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2012 17
3.2.1 Top Initial Public Offerings in Q4 2012 18
3.2.2 Top Secondary Offerings in Q4 2012 18
3.2.3 Top PIPE Deals in Q4 2012 18
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2011–Q4 2012 19
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2011 – Q4 2012 20
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2012 21
3.3.1 Top Venture Financing Deals in Q4 2012 22
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2012 23
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2012 24
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2011 – Q4 2012 25
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 26
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 27
3.3.7 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2012 28
3.3.8 Top Private Equity Deals in Q4 2012 29
3.3.9 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2011 – Q4 2012 30
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2012 31
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2012 31
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2011 – Q4 2012 33
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 34
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2012 35
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2012 35
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2012 36
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 – Q4 2012 37
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2011 – Q4 2012 38
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2011 – Q4 2012 39
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 – Q4 2012 40
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2012 41
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2012 41
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2011 – Q4 2012 42
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2012 43
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2012 43
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2012 44
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2011 – Q4 2012 45
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2011 – Q4 2012 46
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2011 – Q4 2012 47
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2011 – Q4 2012 48
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2011 – Q4 2012 49
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 50
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2011 – Q4 2012 50
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2011 – Q4 2012 51
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2011 – Q4 2012 52
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2011 – Q4 2012 53
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2011 – Q4 2012 54
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q4 2011 – Q4 2012 55
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2011 – Q4 2012 56
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 57
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2012 57
7.1.1 Oncology – Deals of the Quarter 58
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2012 59
7.2.1 Central Nervous System – Deals of the Quarter 60
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2012 62
7.3.1 Infectious Disease – Deals of the Quarter 63
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2012 64
7.4.1 Immunology – Deals of the Quarter 65
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2012 66
7.5.1 Metabolic Disorders – Deals of the Quarter 67
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2012 68
7.6.1 Cardiovascular – Deals of the Quarter 69
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2012 70
7.7.1 Gastrointestinal – Deals of the Quarter 71
7.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2012 72
7.8.1 Ophthalmology – Deals of the Quarter 73
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2012 74
7.9.1 Respiratory – Deals of the Quarter 75
7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2012 76
7.10.1 Dermatology – Deals of the Quarter 77
8 Deal Summary by Geography 78
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2012 78
8.1.1 North America – Deals of the Quarter 79
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2012 81
8.2.1 Europe – Deals of the Quarter 82
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2012 83
8.3.1 Asia-Pacific – Deals of the Quarter 84
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2012 85
8.4.1 Rest of the World – Deals of the Quarter 86
9 Pharmaceuticals & Healthcare, Global, Top Advisors 87
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 87
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 88
10 Appendix 89
11 Further Information 93
11.1 Methodology 93
11.2 About GlobalData 93
11.3 Contact Us 94
11.4 Disclosure information 94
11.5 Disclaimer 94
【レポート販売概要】
■ タイトル：事業提携・ライセンシング・投資・M&A動向（四半期別）：Q4 2012■ 英文：Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2012
■ 発行日：2013年1月31日
■ 調査会社：GlobalData
■ 商品コード：GDATA403160305
■ 調査対象地域：グローバル
- 痙性（Spasticity）治療のグローバル臨床試験動向（2014年下半期）Spasticity Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spasticity. It includes an overview of the trial numbers and their recruitment status as per the site of tri …
- Indoor Location Solutions and Services: Challenges, Opportunities & Market OutlookAs many in the industry understand, indoor location has many challenges compared to location determination in an outdoor environment. However, indoor location is more than just an extension of outdoor - it represents its own unique opportunities and challenges as a standalone business opportunity. This report analyzes global market trends, the driving factors, and how technologies and new developm …
- 雪眼鏡の世界市場2016-2020About Snow Goggles Snow sports are popular recreational activities, especially in countries that are closer to the north or south pole and have longer winter seasons. The most popular forms of snow sports include skiing, sledding, and skating. However, the introduction of artificial snow and ice under controlled temperature conditions has facilitated the growth of the snow sports industry in count …
- 大腸菌（ExPEC）ワクチンの世界市場Extra intestinal pathogenic E.coli (ExPEC) is a member of the Enterobacteriaceae bacterial family. It is a leading cause of healthcare-associated (HCA) infections such as bacteraemia, urinary tract infections, neonatal sepsis and meningitis. For bacteraemias, based on a principal diagnosis from US hospital discharge data, there were an 96,560 E. coli bacteraemias in 2013 compared to 46,140 in 2000 …
- 蒸気トラップの世界市場2018-2022About this market The demand for power is increasing constantly across the world. The increasing population worldwide and growth in the global economy are expected to drive this demand. The demand for clean energy is attributable to the population expansion. the increase in energy demand. and stringent emission norms. Although renewable sources and nuclear power contribute to energy production. a …
- 自動車ティプトロニック・トランスミッションの世界市場2016-2020About Tiptronic Transmission Transmission forms a key function of a vehicle powertrain. It is a type of gearbox that moderates the power generated from an internal combustion engine to the wheel axle. Typically, an automotive transmission includes the entire drivetrain, which forms a system of various components such as gearbox, clutch, prop shaft, drive shafts, and differentials among others. An …
- 2014 Current and Emerging Suppliers Of Immunodiagnostic, Microbiology, Cancer Diagnostic, Molecular Diagnostic, Hematology, Coagulation and Blood Banking Instruments and ReagentsThis new report from Venture Planning Group provides analyses of current and emerging suppliers of immunodiagnositc, microbiology, cancer diagnostic, molecular diagnostic, hematology, coagulation and blood banking instruments and reagents. The report presents strategic profiles of 100 major and emerging suppliers of diagnostic products, including their sales, product portfolios, marketing tactics, …
- ドライバー・セーフティの世界市場予測（～2025年）：アイトラッキング/瞬きモニタリング、表情/頭部動き、心拍数モニタリング、圧力/角度ステアリングセンサー、車線逸脱警告The passenger car driver safety market is projected to grow at a CAGR of 6.24% during the forecast period, to reach a market size of USD 3.20 Billion by 2025. A wide array of upcoming infrastructural development projects, increased urbanization, and the rising demand for safety solutions has led to an increase in the demand for driver safety systems. Additionally, technological advancements such a …
- 心調律管理（CRM）医療装置のグローバル市場（2012-2018）The Cardiac Rhythm Management Devices market value is expected to reach US$20.9 billion by 2017, primarily supported by the product types - Cardiac Defibrillators, Cardiac Pacemakers Devices and Cardiac Resynchronization Therapy. Globally, Cardiac Defibrillators and Pacemakers Devices together account for approximately 80% of the market share to support the Cardiac Rhythm Management Devices Indust …
- 世界の菓子類市場のM&A動向（2014年7月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global confectionery market during July 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global confectionery market throughout the month. Additionally, the report provides an overview of all the …
- 内燃エンジンの世界市場分析：燃料別（石油、天然ガス）、サイクル別（2ストローク、4ストローク）、用途別（自動車、航空機、海洋）、セグメント予測The global internal combustion engine market is expected to reach 197 million units by 2022, according to a new study by Grand View Research, Inc. Rising need for fuel efficiency has resulted in engine downsizing and turbocharging, which is expected to escalate market growth over the coming years. Development of several advanced combustion mode such as homogeneous charge compression ignition (HCCI …
- 世界の工業用ダイヤモンド市場2015The Global Industrial Diamond Industry Report 2015 is a professional and in-depth study on the current state of the Industrial Diamond industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Industrial Diamond market analysis is provided for the international markets including development trends, competiti …
- エアボーンLiDARの世界市場予測（～2022年）“The airborne LiDAR market is projected to grow at a CAGR of 17.32% from 2017 to 2022” The airborne LiDAR market is projected to grow from an estimated USD 1,140.1 million in 2017 to reach USD 2,533.7 million by 2022, at a CAGR of 17.32% from 2017 to 2022. The airborne LiDAR market has been rapidly growing, especially in the Asia Pacific region, owing to the rapid infrastructural development and r …
- エボラウイルスワクチンの世界市場機会分析Ebola virus is a member of the Filoviridae family, which can cause a zoonotic disease in humans. The virus can be transmitted between humans via contact with infected body fluids or large droplets of infected fluids, causing a sudden disease with flu-like symptoms, digestive disorders and hemorrhaging. The mean case fatality of historical outbreaks is around 65%. Most Ebola outbreaks occur in cent …
- 電気ヒューズの世界市場2017-2021About Electric Fuse MarketA fuse prevents electricity overload that protects electrical and electronic devices connected to the circuit. Electric fuses have different applications and the voltage requirement for each of these applications is different. Technavio’s analysts forecast the global electric fuse market to grow at a CAGR of 4.42% during the period 2017-2021. [Covered in this report] The …
